We've detected an Ad Blocker in your browser.

Please disable or pause the Ad Blocker and refresh the page to be able to register and access the website normally.

Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?

BROADCAST SERIES

This broadcast series is supported by an unrestricted educational grant from AstraZeneca


Register Now For Free

Log in

Already registered? Please log in using your email address.

Please enter your email address

Having trouble logging in? Please email info@radcliffe-group.com

validation result

Please choose one of the options shown

Please enter your registration lead id

Please enter your registration session id

Please enter your successful log-in count

first log-in conversion cutoff date (yyyy-mm-dd)

Please choose one of the options shown

event count (i.e. for event number 3, enter 3)

Please choose one of the options shown

on-demand log-in

Please choose one of the options shown

DAYS
:

HOURS
:

MINS
:

SECS

Programme Overview

This broadcast series Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? will reappraise potent P2Y12 inhibitors, as evidence accumulates to support their broader use. At this juncture, there is still some uncertainty around patient selection, initiation and long-term management.

Join us as we consider current guidance, the landmark data, gaps in evidence and seek to provide practical guidance from experts in the field.

This programme is aimed at a target audience of general cardiologists, interventional cardiologists, neurologists, nurses, and any other allied HCPs.

There are four broadcasts in this series focusing on the following key areas:

  • Acute Coronary Syndrome (ACS) – available on-demand now
  • Chronic Coronary Syndrome (CCS) – available on-demand now
  • Balancing Risk Post-PCI – available on-demand now
  • Stroke Prevention – available on-demand now

Catch up now on previous broadcasts using the links below.


The next broadcast starts in:

DAYS
:

HOURS
:

MINS
:

SECS

Agenda

BROADCAST 1
NEXT EVENT

Acute Coronary Syndrome (ACS)

Date: Monday 27 June 2022

Learning objectives
  • Recall current unmet needs in ACS
  • Summarise current use of antiplatelet therapy in ACS according to guidelines
  • Describe the mode of action of potent P2Y12 inhibitors
  • Identify settings where a potent P2Y12 inhibitor should be used in favour of clopidogrel
  • Summarise the results of head-to-head trials between clopidogrel and potent P2Y12 inhibitors
  • Select appropriate assessment criteria for ischaemic risk and bleeding risk
  • Identify patients in whom a medical therapy only approach could be used over invasive strategies
  • Use antiplatelet therapy effectively and safely for long-term management of ACS

Faculty
Prof Robert F. Storey
University of Sheffield, UK
Prof Roxana Mehran - Panelist
Mount Sinai Hospital, New York, US
Prof Dominick J. Angiolillo - Panelist
University of Florida College of Medicine-Jacksonville, US

Prof Kurt Huber - Panelist
Clinic Ottakring, Vienna, AT

BROADCAST 2
NEXT EVENT

Chronic Coronary Syndrome (CCS)

Date: Monday 26 September 2022

Learning objectives

Following the completion of this programme, physicians will be in a position to:

  • Discuss the disease burden in both primary and secondary prevention patients with high-risk features
  • Identify clinical features that make CCS patients high risk
  • Choose an appropriate antiplatelet regimen for CCS patients based on relevant history and current risk profile
  • Recall the results of RCTs using potent P2Y12 inhibitors in CCS patients with a prior MI and in patients with existing diabetes, with/without MI

Faculty
Prof Philippe Gabriel Steg - Chair & Panelist
Bichat-Claude Bernard Hospital, Paris, FR
Dr Marc Bonaca - Panelist
University of Colorado School of Medicine, Aurora, US

Prof Deepak Bhatt - Panelist
Brigham and Women's Hospital, Boston, US

BROADCAST 3
NEXT EVENT

Balancing Risk Post-PCI

Date: Monday 31 October 2022

Learning objectives

  • Apply the use of validated bleeding risk tools across a wide range of patients
  • Use guidelines and clinical judgement to select antiplatelet therapy regimens in patients at elevated bleeding risk
  • Recall the clinical significance of trial data assessing truncated periods of DAPT
  • Prescribe confidently in patients judged to be at elevated bleeding risk
  • Recall the safety profiles of different P2Y12 inhibitors


Faculty
Prof Roxana Mehran - Chair & Panelist
Mount Sinai Hospital, New York, US
Prof Dominick J. Angiolillo - Panelist
University of Florida College of Medicine-Jacksonville, US

Prof Marco Valgimigli - Panelist
Instituto Cardiocentro Ticino, Lugano, CH

Prof Pascal Vranckx - Panelist
University of Hasselt, BE

BROADCAST 4
NEXT EVENT

Stroke Prevention

Date: Monday 13 February 2023

Learning objectives

Following the completion of this programme, physicians will be in a position to:

  • Recall recent trial data for antiplatelet therapies in secondary stroke prevention
  • Apply clinical judgement and trial data to develop optimal antiplatelet strategies in noncardioembolic stroke & TIA
  • Use guidance and recent trial data to formulate optimal antiplatelet strategies in large artery atherosclerosis
  • Confidently prescribe potent antiplatelet therapies by balancing ischaemic and bleeding risk


Faculty
Prof Clay Johnston - Chair & Panelist
Harbor Health, Texas, US
Prof Philippe Gabriel Steg - Panelist
Bichat-Claude Bernard Hospital, Paris, FR

Dr Shelagh Coutts - Panelist
University of Calgary, CA

Prof Jesse Dawson - Panelist
University of Glasgow, UK

Programme Faculty

Broadcast 4

Prof Clay Johnston
Prof Clay Johnston

Chair & Panelist

Harbor Health, Texas, US

Prof Philippe Gabriel Steg
Prof Philippe Gabriel Steg

Panelist

Bichat-Claude Bernard Hospital, Paris, FR

Dr Shelagh Coutts
Dr Shelagh Coutts

Panelist

University of Calgary, CA

Prof Jesse Dawson
Prof Jesse Dawson

Panelist

University of Glasgow, UK

Broadcast 3

Prof Roxana Mehran
Prof Roxana Mehran

Chair & Panelist

Mount Sinai Hospital, New York, US

Prof Dominick J. Angiolillo
Prof Dominick J. Angiolillo

Panelist

University of Florida College of Medicine-Jacksonville, US

Prof Marco Valgimigli
Prof Marco Valgimigli

Panelist

Instituto Cardiocentro Ticino, Lugano, CH

Prof Pascal Vranckx
Prof Pascal Vranckx

Panelist

University of Hasselt, BE

Broadcast 2

Philippe Gabriel Steg
Prof Philippe Gabriel Steg

Chair & Panelist

Bichat-Claude Bernard Hospital, Paris, FR

Deepak Bhatt
Prof Deepak Bhatt

Panelist

Brigham and Women's Hospital, Boston, US

Marc Bonaca
Dr Marc Bonaca

Panelist

University of Colorado School of Medicine, Aurora, US

Broadcast 1

Prof Robert F. Storey
Prof Robert F. Storey

Chair & Panelist

University of Sheffield, UK

Prof Dominick J. Angiolillo
Prof Dominick J. Angiolillo

Panelist

University of Florida College of Medicine-Jacksonville, US

Prof Kurt Huber
Prof Kurt Huber

Panelist

Clinic Ottakring, Vienna, AT

Prof Roxana Mehran
Prof Roxana Mehran

Panelist

Mount Sinai Hospital, New York, US

Register Now